Salix Looks to Actavis After Terminating Cosmo Deal
New rules from the Treasury Department regarding inversion affect merger activity in the pharmaceutical sector.
Citing recent tax rules, Salix terminated their proposed merger with Cosmo Pharmaceuticals’ Irish subsidiary and is now in takeover discussions with Actavis, reports FirstWord Pharma. Salix backed out of its agreement with Cosmo when it realized it could no longer benefit from the corporate tax structure overseas. Carolyn Logan, president and CEO of Salix, said in a statement, “the changed political environment has created more uncertainty regarding the potential benefits we expected to achieve.”
Instead, Salix is reportedly looking to sell itself to Actavis after a deal with Allergan went sour. The New York Times reports that acquiring Salix would mean that Actavis could be too large to be acquired by Pfizer, which approached Actavis about a takeover earlier this year.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
